Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aminophenazone is a small molecule analgesic and antipyretic of the pyrazolone class, historically used for pain relief and fever reduction in conditions such as rheumatism, neuritis, pulmonary tuberculosis, and common colds. It was also used in combination with ergotamine and caffeine for acute migraine attacks. Aminophenazone acts as an anti-inflammatory agent but carries a significant risk of life-threatening agranulocytosis, which led to its withdrawal from many markets. The drug has also been utilized in radiolabeled form (13C-labeled) for non-invasive liver function tests measuring cytochrome P450 metabolic activity. Its mechanism involves inhibition of prostaglandin synthesis via cyclooxygenase inhibition[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aminophenazone.